Deflazacort: Fa'aoga, Totogi, Itu Aafiaga ma isi

Folasaga: O le a le Deflazacort?

If you or a loved one are managing an autoimmune disease, inflammatory disorder, or a specific type of cancer, your doctor may have prescribed Deflazacort. This corticosteroid medication is primarily used to reduce inflammation and suppress the immune system.

It is similar to other corticosteroids but is known for a lower risk of certain side effects, particularly bone mineral density loss and weight gain, making it a valuable option for various conditions, including Duchenne muscular dystrophy.

Fa'ailoga ma Fa'aoga

FDA-Approved Indication

Deflazacort (brand name: Emflaza) is FDA-approved for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

DMD is a rare, inherited muscle disease characterised by progressive muscle degeneration and weakness, caused by an absence of the protein dystrophin.

Deflazacort is the only corticosteroid with a specific FDA approval for DMD.

Off-Label Use in India

In Indian clinical practice, deflazacort is widely prescribed off-label as a corticosteroid for various inflammatory and autoimmune conditions. These uses are based on clinical experience and regional prescribing patterns; they are not FDA-approved indications.

Common off-label uses include:

• Fa'aletonu o le autoimmune: Rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune hepatitis
• Tulaga fulafula: Asthma, inflammatory bowel disease (IBD), nephrotic syndrome
• Tulaga fa'ama'i: Severe allergic reactions, allergic rhinitis (in moderate to severe cases only)
• Dermatological conditions: Severe eczema, pemphigus, and other autoimmune skin disorders
• Totogi totoga: As part of immunosuppressive regimens to prevent graft rejection
• O nisi kanesa: As part of treatment regimens for specific haematological malignancies, including leukaemia and lymphoma

Deflazacort is not recommended for mild allergies or conditions that can be managed with non-steroidal anti-inflammatory drugs. It should be used only when the clinical situation warrants corticosteroid therapy, as determined by the prescribing physician.

Faapefea E Galuega

Deflazacort works by mimicking the effects of hormones produced by the adrenal glands, particularly cortisol.

E fa'aitiitia ai le mumū e ala i le taofia o le fa'asa'olotoina o vaila'au i totonu o le tino e mafua ai le mumū ma tali atu i le puipuiga o le tino.

I se faaupuga faigofie, e faʻafilemuina ai le puipuiga o le tino ma faʻaitiitia ai le fula, mumu, ma le tiga e fesoʻotaʻi ma le tele o tulaga.

After oral administration, deflazacort is rapidly converted to its active metabolite, 21-desacetyldeflazacort, which is responsible for its therapeutic effects.

Totoga

DMD Dosing (FDA-Approved)

• Adults and children aged 2 years and older: 0.9 mg/kg/day, administered once daily
• Available formulations: Tablets (6 mg, 18 mg, 30 mg, 36 mg) and oral suspension (22.75 mg/mL)
• If using tablets, round up to the nearest possible dose; any combination of tablet strengths may be used to achieve the calculated dose
• If using oral suspension, round up to the nearest tenth of a millilitre (mL)

Off-Label Dosing (India)

For off-label inflammatory and autoimmune indications, the typical adult dose ranges from 6 to 48 mg/day, depending on the condition, severity, and clinical response.

The dose is usually started at a higher level and tapered gradually to the lowest effective maintenance dose.

Dosing should always be individualised under medical supervision.

For children (off-label), the dosage is typically based on body weight, ranging from 0.5 to 1.5 mg/kg/day depending on the condition and severity.

Take deflazacort with or without food. Swallow the tablet whole.

Mulimuli i faatonuga a lau tausi soifua maloloina.

Afai ua misi se tui, ave loa pe a e manatua. Afai e latalata i le taimi mo lau isi tui, fa'amisi le fua na misi ma toe amata lau fa'asologa masani. Aua ne'i faaluaina le fua e toe sui ai le mea ua misi.

Faamatalaga Taua o le Saogalemu

Itu a'afiaga o Deflazacort

While Deflazacort can be effective, it may also cause side effects.

Faʻasologa o Itu Masani

• Tupe mama
• Faateleina le manaʻo
• Suiga o lagona (faataitaiga, popole, atuatuvale)
• moe fiti
• Le maualuga o le suka toto

O aʻafiaga ogaoga

• Faʻateleina le lamatiaga o faʻamaʻi pipisi
• Osteoporosis (fa'iviivi)
• Fa'afitauli ole gastrointestinal (fa'ata'ita'iga, papala)
• Fa'afitauli o mata (fa'ata'ita'iga, fa'ata, glaucoma)
• Adrenal suppression (le mafaia e le tino ona gaosia ni vailaʻau faʻanatura)

Tafaoga faʻamalosi

Deflazacort e mafai ona fegalegaleai ma le tele o vailaʻau ma vailaʻau, e aofia ai:

• O mea e taofia ai le CYP3A4: Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and ritonavir) can increase deflazacort levels. If co-administration cannot be avoided, the deflazacort dose should be reduced to one-third of the recommended dose.
• CYP3A4 inducers: Drugs such as rifampicin, carbamazepine, phenytoin, and phenobarbital can reduce deflazacort levels, potentially decreasing its effectiveness.
• Anetikerau: E pei o le warfarin, atonu e iai ni suiga.
• Vailaau fa'ama'i suka: Atonu e mana'omia ni fetuunaiga ona o le si'itia o le toto suka.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): Fa'atupula'ia le lamatiaga o le tafe toto o le manava.
• Tui puipui: Live-attenuated vaccines are contraindicated. Killed or inactivated vaccines may have reduced immunological response during corticosteroid therapy.

Fa'ailoa i taimi uma lau 'au'aunaga fa'alesoifua maloloina e uiga i vaila'au uma ma fa'aopoopoga o lo'o e inuina ina ia 'alofia ai fegalegaleaiga e ono tutupu mai.

Fa'amanuiaga ole Deflazacort

Despite the risks associated with long-term corticosteroid use, deflazacort offers several benefits when used appropriately:

• DMD: Faʻavae In Duchenne muscular dystrophy, deflazacort has been shown to prolong ambulation (ability to walk), slow the decline of muscle strength, reduce the risk of scoliosis, and delay the onset of cardiomyopathy and respiratory decline.
• Comparatively bone-sparing: Compared with other corticosteroids such as prednisone, deflazacort has been associated with a lower impact on bone mineral density, making it a preferred choice when long-term corticosteroid therapy is required.
• Anti-inflammatory efficacy: Effective in reducing inflammation and immune-mediated tissue damage in a range of autoimmune and inflammatory conditions.
• Immunosuppression: Useful in managing conditions where suppression of the immune system is required, including organ transplant recipients.

Contraindications ole Deflazacort

O nisi tagata e tatau ona aloese mai le faʻaaogaina o Deflazacort, e aofia ai:

• Tina ma’itaga: E ono afaina ai le pepe. O lona fa'aogaina e tatau ona va'ai toto'a, ma e ono mana'omia se su'ega o le ma'itaga a'o le'i amataina togafitiga pe a mafai.
• Tagata ta'ito'atasi o lo'o maua i fa'ama'i pipisi: E mafai ona taofiofia le puipuiga o le tino, ma matua faateleina ai le lamatiaga o le faateteleina poʻo le faʻasalalauina o faʻamaʻi.
• O ma'i e iai tulaga fa'alesoifua maloloina: E pei o le ma'i ogaoga o le ate, ma'i ma'isuka e le pulea.

Fa'afeso'ota'i i taimi uma se tausi soifua maloloina e iloa ai pe talafeagai Deflazacort mo lou tulaga.

Lapataiga ma Lapataʻiga

Aʻo leʻi amataina le Deflazacort, mafaufau i lapataiga nei:

• Mata'ituina masani: E ono mana'omia e tagata ma'i ni su'ega toto e mata'ituina ai le maualuga o le suka o le toto, galuega o le ate, ma isi vaega.
• Fa'ato'a fa'asolosolo: Afai na e i ai i luga o le Deflazacort mo se vaitaimi umi, e taua tele le tape malie o le vailaʻau e aloese ai mai faʻamaʻi faʻamavae.
• Tui: Talanoaina fuafuaga o tui ma lau tausi soifua maloloina, aemaise lava ile tui ola.
• A'afiaga Fa'ama'i: Ia mataala mo so'o se fa'ailoga o fa'ama'i (fiva, tiga fa'a'i, fa'atupula'ia le tiga), ma lipoti vave atu i lau foma'i, ona e ono fa'aletonu lou tino.

Fesili e masani ona fesiligia (FAQs)

O le a le mea e faʻaaogaina ai Deflazacort?

Deflazacort is FDA-approved for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older. In India, it is also widely used off-label for autoimmune and inflammatory conditions such as rheumatoid arthritis, asthma, nephrotic syndrome, and severe allergic conditions.

What is the correct dose for DMD?

The FDA-approved dose for DMD is 0.9 mg/kg/day, administered once daily. The dose is based on the patient’s body weight and should be calculated by the prescribing physician.

E tatau faapefea ona ou ave Deflazacort?

E masani ona ave tautala ile laulau po'o le tu'iina, e pei ona fa'atonuina e lau tausi soifua maloloina.

O a a'afiaga masani?

O a'afiaga masani e aofia ai le maua o le mamafa, faateleina le fia'ai, suiga o lagona, ma le le mautonu.

Can I stop deflazacort suddenly?

No. Deflazacort must not be stopped abruptly after prolonged use. Doses should be tapered gradually under medical supervision to avoid adrenal crisis.

E mafai ona ou inu Deflazacort pe a ou maʻitaga?

Deflazacort should be used during pregnancy only if the potential benefit justifies the risk to the foetus. There are no adequate human studies. Discuss with your doctor.

Can I receive vaccines while on deflazacort?

Live vaccines are contraindicated during immunosuppressive doses. Killed or inactivated vaccines may be given but may have a reduced response. All vaccinations should ideally be completed before starting deflazacort.

Is deflazacort the same as prednisolone?

No. While both are corticosteroids, deflazacort is a distinct drug with a different pharmacological profile.

Studies suggest deflazacort may have a comparatively lower impact on bone mineral density and weight gain than prednisone/prednisolone, which is one reason it is preferred for long-term use in DMD.

E faʻafefea ona galue Deflazacort?

E fa'ata'ita'i i hormones fa'anatura e fa'aitiitia ai le fula ma taofia le tali atu.

E iai ni a'afiaga ogaoga?

Ioe, o a'afiaga ogaoga e mafai ona aofia ai le fa'ateleina o fa'ama'i pipisi, osteoporosis, ma fa'afitauli o le manava.

E mafai ona ou taofi faʻafuaseʻi le inu Deflazacort?

Leai, e taua le tape malie o le vailaʻau i lalo o le vaavaaiga a fomaʻi e aloese ai mai faʻamaoniga o le toesea.

O le a le mea e tatau ona ou faia pe a ou misia se tui?

Ave le tui ua misi i le taimi lava e te manatua ai, ae fa'amisi pe a toeitiiti o'o i le taimi mo lau isi tui. Aua le faaluaina.

E mafai e Deflazacort ona fegalegaleai ma isi vailaʻau?

Ioe, e mafai ona fegalegaleai ma anticoagulants, vailaʻau antidiabetic, ma NSAIDs, ma isi.

O le a le umi e mafai ona ou ave ai le Deflazacort?

Ole umi ole togafitiga e eseese ile tulaga o lo'o togafitia. Mulimuli i fautuaga a lau foma'i mo se taunuuga lelei.

Does deflazacort affect blood sugar levels?

Yes. Deflazacort can cause hyperglycaemia (elevated blood sugar) and may unmask latent diabetes or worsen existing diabetes.

Blood glucose levels should be monitored regularly, particularly during long-term use.

Should children on deflazacort for DMD be monitored differently?

Yes. Paediatric patients on long-term deflazacort for DMD require regular monitoring of growth, bone mineral density, blood glucose, ophthalmological examinations, and adrenal function.

Your child’s doctor will schedule these assessments.

Igoa Igoa

Deflazacort o loʻo maketiina i lalo o le tele o igoa, e aofia ai:

• Emflaza
• Deflazacort
• Deflazacort Sandoz

iʻuga

Deflazacort is a versatile corticosteroid medication that plays a crucial role in managing various inflammatory and autoimmune conditions.

E ui e ofoina mai ai ni fa'amanuiaga taua, e aofia ai le maualalo o le lamatiaga o nisi o a'afiaga pe a fa'atusatusa i isi corticosteroids, ae e taua tele le nofouta i a'afiaga uma e ono tula'i mai ma fegalegaleaiga o vaila'au.

Ia feutagai i taimi uma ma lau fomaʻi e fuafua ai le fuafuaga togafitiga sili ona lelei e fetaui ma ou manaʻoga, ma ia faʻaauau pea ona talanoa e uiga i soʻo se faʻailoga fou pe faʻateteleina, aemaise lava pe a faʻaaogaina mo se taimi umi pe a fetuʻunaʻi le inumaga.